Nifedipine in unstable angina. A double-blind, randomized trial

Gary Gerstenblith, Pamela Ouyang, Stephen C Achuff, B. H. Bulkley, Lewis Becker, E. D. Mellits, K. L. Baughman, James L Weiss, J. T. Flaherty, C. H. Kallman, M. Llewellyn, Myron Weisfeldt

Research output: Contribution to journalArticle

Abstract

We assessed the efficacy of adding nifedipine to the conventional treatment of unstable angina in 138 patients in a prospective, double-blind, randomized, placebo-controlled trial. There was no difference between the two groups in the dose of conventional antianginal medication or in age, prior myocardial infarction, ejection fraction, or other risk factors. Failure of medical treatment (defined as sudden death, myocardial infarction, or bypass surgery within four months) occurred in 43 of 70 patients given placebo and in 30 of 68 given nifedipine. Kaplan-Meier survival-curve analysis of the number and time dependence of treatment failures demonstrated a benefit of nifedipine over placebo (P = 0.03). The benefit was particularly marked in patients with ST-segment elevation during angina (P = 0.02). Side effects (transient hypotension or diarrhea) required withdrawal of the drug from four patients given nifedipine and from one given placebo. We conclude that the addition of nifedipine to conventional therapy is safe and effective in unstable angina.

Original languageEnglish (US)
Pages (from-to)885-889
Number of pages5
JournalNew England Journal of Medicine
Volume306
Issue number15
StatePublished - 1982

Fingerprint

Unstable Angina
Nifedipine
Placebos
Treatment Failure
Myocardial Infarction
Kaplan-Meier Estimate
Survival Analysis
Sudden Death
Hypotension
Diarrhea
Randomized Controlled Trials
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nifedipine in unstable angina. A double-blind, randomized trial. / Gerstenblith, Gary; Ouyang, Pamela; Achuff, Stephen C; Bulkley, B. H.; Becker, Lewis; Mellits, E. D.; Baughman, K. L.; Weiss, James L; Flaherty, J. T.; Kallman, C. H.; Llewellyn, M.; Weisfeldt, Myron.

In: New England Journal of Medicine, Vol. 306, No. 15, 1982, p. 885-889.

Research output: Contribution to journalArticle

Gerstenblith, G, Ouyang, P, Achuff, SC, Bulkley, BH, Becker, L, Mellits, ED, Baughman, KL, Weiss, JL, Flaherty, JT, Kallman, CH, Llewellyn, M & Weisfeldt, M 1982, 'Nifedipine in unstable angina. A double-blind, randomized trial', New England Journal of Medicine, vol. 306, no. 15, pp. 885-889.
Gerstenblith, Gary ; Ouyang, Pamela ; Achuff, Stephen C ; Bulkley, B. H. ; Becker, Lewis ; Mellits, E. D. ; Baughman, K. L. ; Weiss, James L ; Flaherty, J. T. ; Kallman, C. H. ; Llewellyn, M. ; Weisfeldt, Myron. / Nifedipine in unstable angina. A double-blind, randomized trial. In: New England Journal of Medicine. 1982 ; Vol. 306, No. 15. pp. 885-889.
@article{48664c148149416f80444b1533caab52,
title = "Nifedipine in unstable angina. A double-blind, randomized trial",
abstract = "We assessed the efficacy of adding nifedipine to the conventional treatment of unstable angina in 138 patients in a prospective, double-blind, randomized, placebo-controlled trial. There was no difference between the two groups in the dose of conventional antianginal medication or in age, prior myocardial infarction, ejection fraction, or other risk factors. Failure of medical treatment (defined as sudden death, myocardial infarction, or bypass surgery within four months) occurred in 43 of 70 patients given placebo and in 30 of 68 given nifedipine. Kaplan-Meier survival-curve analysis of the number and time dependence of treatment failures demonstrated a benefit of nifedipine over placebo (P = 0.03). The benefit was particularly marked in patients with ST-segment elevation during angina (P = 0.02). Side effects (transient hypotension or diarrhea) required withdrawal of the drug from four patients given nifedipine and from one given placebo. We conclude that the addition of nifedipine to conventional therapy is safe and effective in unstable angina.",
author = "Gary Gerstenblith and Pamela Ouyang and Achuff, {Stephen C} and Bulkley, {B. H.} and Lewis Becker and Mellits, {E. D.} and Baughman, {K. L.} and Weiss, {James L} and Flaherty, {J. T.} and Kallman, {C. H.} and M. Llewellyn and Myron Weisfeldt",
year = "1982",
language = "English (US)",
volume = "306",
pages = "885--889",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "15",

}

TY - JOUR

T1 - Nifedipine in unstable angina. A double-blind, randomized trial

AU - Gerstenblith, Gary

AU - Ouyang, Pamela

AU - Achuff, Stephen C

AU - Bulkley, B. H.

AU - Becker, Lewis

AU - Mellits, E. D.

AU - Baughman, K. L.

AU - Weiss, James L

AU - Flaherty, J. T.

AU - Kallman, C. H.

AU - Llewellyn, M.

AU - Weisfeldt, Myron

PY - 1982

Y1 - 1982

N2 - We assessed the efficacy of adding nifedipine to the conventional treatment of unstable angina in 138 patients in a prospective, double-blind, randomized, placebo-controlled trial. There was no difference between the two groups in the dose of conventional antianginal medication or in age, prior myocardial infarction, ejection fraction, or other risk factors. Failure of medical treatment (defined as sudden death, myocardial infarction, or bypass surgery within four months) occurred in 43 of 70 patients given placebo and in 30 of 68 given nifedipine. Kaplan-Meier survival-curve analysis of the number and time dependence of treatment failures demonstrated a benefit of nifedipine over placebo (P = 0.03). The benefit was particularly marked in patients with ST-segment elevation during angina (P = 0.02). Side effects (transient hypotension or diarrhea) required withdrawal of the drug from four patients given nifedipine and from one given placebo. We conclude that the addition of nifedipine to conventional therapy is safe and effective in unstable angina.

AB - We assessed the efficacy of adding nifedipine to the conventional treatment of unstable angina in 138 patients in a prospective, double-blind, randomized, placebo-controlled trial. There was no difference between the two groups in the dose of conventional antianginal medication or in age, prior myocardial infarction, ejection fraction, or other risk factors. Failure of medical treatment (defined as sudden death, myocardial infarction, or bypass surgery within four months) occurred in 43 of 70 patients given placebo and in 30 of 68 given nifedipine. Kaplan-Meier survival-curve analysis of the number and time dependence of treatment failures demonstrated a benefit of nifedipine over placebo (P = 0.03). The benefit was particularly marked in patients with ST-segment elevation during angina (P = 0.02). Side effects (transient hypotension or diarrhea) required withdrawal of the drug from four patients given nifedipine and from one given placebo. We conclude that the addition of nifedipine to conventional therapy is safe and effective in unstable angina.

UR - http://www.scopus.com/inward/record.url?scp=0020032732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020032732&partnerID=8YFLogxK

M3 - Article

C2 - 7038491

AN - SCOPUS:0020032732

VL - 306

SP - 885

EP - 889

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 15

ER -